Publications by authors named "Roxanne Wood"
Background: Immune checkpoint inhibitors alone, or in combination with chemotherapy failed to provide meaningful clinical activity for patients with microsatellite stable (MSS) colorectal cancer (CRC). ONC201 is a small molecule that inactivates AKT and ERK signaling and actives the TRAIL pathway. Preclinical studies indicated potential benefits of combining ONC201 with checkpoint inhibitors.
View Article and Find Full Text PDFBackground: Newly diagnosed multiple myeloma patients have many available treatment options. While lenalidomide, bortezomib, and dexamethasone (RVD) is the preferred initial treatment for many patients, several other agents may provide similar efficacy with less toxicity and improved ease of administration.
Methods: We evaluated the safety and efficacy of the all-oral regimen of ixazomib, cyclophosphamide, and dexamethasone with the use of metronomic cyclophosphamide dosing in the treatment of patients with newly diagnosed multiple myeloma.
Article Synopsis
- The study assessed the effectiveness, side effects, and response rates of a new chemotherapy combination (FOLFOX-A) in patients with advanced pancreatic cancer.
- Two phase II studies were conducted, enrolling 78 patients to evaluate the treatment's response, with results indicating a 34% overall response rate and varying progression-free and overall survival rates based on the study group.
- The treatment showed significant promise with manageable side effects, suggesting it could be a viable alternative to another chemotherapy regimen with less gastrointestinal toxicity.
Article Synopsis
- The study explored the safety and toxicity of combining nivolumab and low-dose ipilimumab in high-risk patients with completely resected melanoma.
- Out of 21 patients, 48% experienced grade 3 treatment-related toxicities, but there were no severe cases (grade 4 or 5), and 71% completed the full treatment.
- With a median follow-up of 41 months, the 2-year recurrence-free survival rate was 85.7% and overall survival rate was 90.5%, suggesting this treatment could be beneficial, warranting further research.
Background: Liposomal formulations may improve the solubility and bioavailability of drugs potentially increasing their ability to cross the blood-brain barrier. We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in patients with recurrent glioblastoma.
Patients And Methods: Patients with glioblastoma who progressed after at least 1 line of therapy were eligible.
Sexuality is an important aspect of life and is often affected in patients diagnosed with cancer. For women, estimates of sexual dysfunction range from 40 to 100%. In light of these statistics, we were interested in determining the comfort level and practice of specialists in gynecologic oncology as it relates to taking a sexual history and addressing related concerns by conducting a survey of the New England Association of Gynecologic Oncologists (NEAGO).
View Article and Find Full Text PDF